Scholarlink

<p>Biosimilars produced in plant systems encompass a range of molecules, including antibodies, vaccines, enzymes, receptors, and other therapeutic molecules. In the present study, we aimed to express the immune checkpoint-inhibitor anti-CTLA-4 antibody, Ipilimumab, in <i>Nicotiana tabacum</i> plant. We generated transgenic tobacco plants using <i>Agrobacterium</i>-mediated transformation and purified an anti-CTLA-4 monoclonal antibody (mAb<sup>P</sup> CTLA-4) using protein A affinity chromatography. This purified mAb<sup>P</sup> CTLA-4 showed specific binding activity to CTLA-4-positive human tonsil tissues, as confirmed by immunoblot, indirect ELISA, and immunohistochemistry analyses. Our study confirmed that mAb<sup>P</sup> CTLA-4 effectively targeted CTLA-4 in human tonsil tissues. These findings suggest that our plant-derived anti-CTLA-4 antibody retains its original functionality, underscoring the promising potential of plant-based therapeutic expression systems for producing high-value medicinal biosimilars.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Expression and in vitro function of anti-CTLA-4 human antibody expressed in plants

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月3日

查看全文
  • Chae Eun Lee,
  • Jeong Hwan Lee,
  • Hyun Joo Chung,
  • Sohee Lim,
  • Da Won Lee,
  • Jong Seok Lim,
  • Jin Wook Kim,
  • Soon Auck Hong,
  • Min Eui Hong,
  • Joo Young Kim,
  • Hye Jun Lee,
  • Kisung Ko,
  • Soon Chul Myung

摘要

Biosimilars produced in plant systems encompass a range of molecules, including antibodies, vaccines, enzymes, receptors, and other therapeutic molecules. In the present study, we aimed to express the immune checkpoint-inhibitor anti-CTLA-4 antibody, Ipilimumab, in Nicotiana tabacum plant. We generated transgenic tobacco plants using Agrobacterium-mediated transformation and purified an anti-CTLA-4 monoclonal antibody (mAbP CTLA-4) using protein A affinity chromatography. This purified mAbP CTLA-4 showed specific binding activity to CTLA-4-positive human tonsil tissues, as confirmed by immunoblot, indirect ELISA, and immunohistochemistry analyses. Our study confirmed that mAbP CTLA-4 effectively targeted CTLA-4 in human tonsil tissues. These findings suggest that our plant-derived anti-CTLA-4 antibody retains its original functionality, underscoring the promising potential of plant-based therapeutic expression systems for producing high-value medicinal biosimilars.